Insider Selling: Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Sells 15,143 Shares of Stock

Abrdn Life Sciences Investors (NYSE:HQL) major shareholder Saba Capital Management, L.P. sold 15,143 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $14.27, for a total transaction of $216,090.61. Following the completion of the sale, the insider now owns 3,381,371 shares of the company’s stock, valued at approximately $48,252,164.17. The trade was a 0.45 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, January 29th, Saba Capital Management, L.P. sold 11,674 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $14.12, for a total value of $164,836.88.

Abrdn Life Sciences Investors Price Performance

Shares of Abrdn Life Sciences Investors stock traded down $0.21 during trading on Monday, hitting $14.01. 170,163 shares of the company’s stock traded hands, compared to its average volume of 115,032. The firm’s fifty day moving average price is $13.77 and its 200 day moving average price is $14.59. Abrdn Life Sciences Investors has a twelve month low of $12.76 and a twelve month high of $15.90.

Abrdn Life Sciences Investors Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 10th. Shareholders of record on Thursday, November 21st were given a $0.50 dividend. The ex-dividend date was Thursday, November 21st. This is a positive change from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.49. This represents a $2.00 dividend on an annualized basis and a yield of 14.28%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of HQL. Future Financial Wealth Managment LLC acquired a new stake in Abrdn Life Sciences Investors during the 3rd quarter valued at $30,000. Ashton Thomas Securities LLC acquired a new position in Abrdn Life Sciences Investors during the 3rd quarter worth about $148,000. Kapstone Financial Advisors LLC bought a new stake in Abrdn Life Sciences Investors during the 3rd quarter worth about $177,000. Sanctuary Advisors LLC acquired a new stake in Abrdn Life Sciences Investors in the 2nd quarter valued at about $154,000. Finally, Kingswood Wealth Advisors LLC acquired a new position in shares of Abrdn Life Sciences Investors during the fourth quarter worth approximately $160,000. 32.21% of the stock is owned by institutional investors and hedge funds.

About Abrdn Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.